ClinicalTrials.gg
CompletedNCT03846427MAGNOLIAUpdated Oct 26, 2024Results posted

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

A Phase 2 interventional study of Zanubrutinib in Marginal Zone Lymphoma and MZL, sponsored by BeiGene. Completed at 31 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Lymphoma, B-Cell, Marginal Zone with a site in Australia — 6 open to participants now, 13 under way, 3 of them phase 3. Lymphoma, B-Cell, Marginal Zone · Australia.

Enrollment
29th of 35
68 · median 120
Started
2019
with 4 others
Phase 2
7 of 36
none open now
Registered
15th of 36
by date
Lead sponsor
2 of 36
BeiGene

Among the 36 studies in Lymphoma, B-Cell, Marginal Zone with a site in Australia, this one is the 29th largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2019, is one of 7 in phase 2, and was the 15th registered.

Lymphoma, B-Cell, Marginal Zone

875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

6 of the 36 studies in Lymphoma, B-Cell, Marginal Zone with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Lymphoma, B-Cell, Marginal Zone with a site in Australia, or all of them as a file.
02

Study summary

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).

03

Conditions studied

  • Marginal Zone Lymphoma
  • MZL

Keywords

  • BGB-3111
  • Zanubrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age 18 years or older
  2. confirmed diagnosis of MZL including splenic, nodal, and extranodal subtypes
  3. Previously received one or more including at least one CD20-directed regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to achieve at least partial response or documented progressive disease (PD) after, the most recent systemic treatment
  4. Current need for systemic therapy for MZL
  5. by computed tomography (CT) or magnetic resonance imaging (MRI)
  6. (ECOG) of 0-2
  7. ≥ 6 months
  8. Adequate bone marrow function
  9. Adequate organ function
  10. Male and female participants must use highly effective methods of

Key Exclusion Criteria:

  1. Known transformation to aggressive lymphoma, eg, large cell lymphoma
  2. cardiovascular disease
  3. Prior within the past 2 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer
  4. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention
  5. History of stroke or intracranial hemorrhage
  6. Severe or debilitating pulmonary disease
  7. Active fungal, bacterial and/or viral infection requiring systemic therapy
  8. Known central nervous system involvement by lymphoma
  9. Known infection with , or serologic status reflecting active viral (HBV) or viral (HCV) infection
  10. Major surgery within 4 weeks of the first dose of study drug
  11. Prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor
  12. Pregnant or lactating women
  13. Requires ongoing treatment with a strong Cytochrome P4503A () inhibitor or inducer
  14. Concurrent participation in another therapeutic clinical trial

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent

    Drug: Zanubrutinib

Interventions

  • Zanubrutinib at a dose of 160 mg orally twice a day (BID)

    Also known as: BGB-3111, Brukinsa

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) by Independent Review Committee (IRC) Assessment

    ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by an IRC using the Lugano Classification

    Time frame: Up to approximately 3 years and 2.5 months

Secondary outcomes

  1. ORR by Investigator Assessment

    ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by the investigator using the Lugano Classification.

    Time frame: Up to approximately 3 years and 2.5 months

  2. ORR by IRC Assessment Using Positron Emission Tomography-Computed Tomography (PET-CT)

    ORR is defined as the percentage of participants with complete and partial response as the best overall response, as determined by an IRC using PET-CT assessment data for participants with fluorodeoxyglucose (FDG)-avid disease

    Time frame: Up to approximately 3 years and 2.5 months

  3. Progression-free Survival (PFS) by Investigator Assessment

    PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using Lugano Classification

    Time frame: Up to approximately 3 years and 2.5 months

  4. PFS Event-Free Rate by Investigator Assessment

    PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for PFS at 24 months with 95% confidence intervals estimated using Greenwood's formula.

    Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported

  5. PFS by IRC Assessment

    PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by an IRC using Lugano Classification

    Time frame: Up to approximately 3 years and 2.5 months

  6. PFS Event-Free Rate by IRC Assessment

    PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for PFS at 24 months with 95% confidence intervals estimated using Greenwood's formula.

    Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported

  7. Overall Survival (OS)

    OS is defined as the time from first study drug administration to the date of death due to any cause

    Time frame: Up to approximately 3 years and 2.5 months

  8. OS Event-Free Rate

    OS is defined as the time from first study drug administration to the date of death due to any cause. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for OS at 24 months with 95% confidence intervals estimated using Greenwood's formula.

    Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported

  9. Duration of Response (DOR) by Investigator Assessment

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification.

    Time frame: Up to approximately 3 years and 2.5 months

  10. DOR Event-Free Rate by Investigator Assessment

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 24 months with 95% confidence intervals estimated using Greenwood's formula.

    Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported

  11. DOR by IRC Assessment

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using Lugano Classification.

    Time frame: Up to approximately 3 years and 2.5 months

  12. DOR Event-Free Rate by IRC Assessment

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 24 months with 95% confidence intervals estimated using Greenwood's formula.

    Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported

  13. Time to Treatment Failure (TTF)

    TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason.

    Time frame: Up to approximately 3 years and 2.5 months

  14. TTF Event-Free Rate

    TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for TTF at 24 months with 95% confidence intervals estimated using Greenwood's formula.

    Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported

  15. Time to Next Line of Therapy

    Time to next line of therapy is defined as the time from study treatment start to the start of the first subsequent therapy for MZL

    Time frame: Up to approximately 3 years and 2.5 months

  16. Time to Next Line of Therapy Event-Free Rate

    Time to next line of therapy is defined as the time from study treatment start to the start of the first subsequent therapy for MZL. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for time to next line of therapy at 24 months with 95% confidence intervals estimated using Greenwood's formula.

    Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported

  17. Time to Response (TTR) by Investigator Assessment

    TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better) as assessed by the investigator using Lugano Classification

    Time frame: Up to approximately 3 years and 2.5 months

  18. TTR by IRC Assessment

    TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better), as assessed by the IRC using Lugano Classification.

    Time frame: Up to approximately 3 years and 2.5 months

  19. Change From Baseline in EuroQol 5-dimension 5-level (EQ-5D-5L) Visual Analogue Score (VAS)

    Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' Positive change from baseline indicates improved health.

    Time frame: Baseline to Cycle 30 (28 days per cycle)

  20. Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status

    Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes global health status and quality of life questions related to their overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a positive score from baseline indicating improved health.

    Time frame: Baseline to Cycle 30 (28 days per cycle)

  21. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory tests, physical exams, and vital signs

    Time frame: From first dose to 30 days after last dose of study drug (Up to approximately 3 years and 2.5 months)

  22. Area Under the Curve From Time 0 to 6 Hours (AUC0-6)

    Time frame: Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)

  23. Apparent Oral Clearance (CL/F) of Zanubrutinib

    Time frame: Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)

  24. Maximum Observed Concentration (Cmax)

    Time frame: Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)

  25. Elimination Half Life (t1/2)

    Time frame: Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)

07

Results

Posted Mar 3, 2022

Participant flow

This study was conducted at 31 study centers in 9 countries.

Participant flow — Overall Study
MilestoneZanubrutinib
Started68
Completed51
Not completed17
Withdrew: Death13
Withdrew: Withdrawal by subject3
Withdrew: Physician decision1

Outcome measures

PrimaryOverall Response Rate (ORR) by Independent Review Committee (IRC) Assessment

ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by an IRC using the Lugano Classification

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) by Independent Review Committee (IRC) Assessment
Percentage of participantsZanubrutinib
Overall Response Rate (ORR) by Independent Review Committee (IRC) Assessment68.2 (55.56 to 79.11)
Statistical analysis
  • Zanubrutinib · Binomial exact method · p = <0.0001
SecondaryORR by Investigator Assessment

ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by the investigator using the Lugano Classification.

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Number · Percentage of participants
ORR by Investigator Assessment
Percentage of participantsZanubrutinib
ORR by Investigator Assessment75.8 (63.64 to 85.46)
SecondaryORR by IRC Assessment Using Positron Emission Tomography-Computed Tomography (PET-CT)

ORR is defined as the percentage of participants with complete and partial response as the best overall response, as determined by an IRC using PET-CT assessment data for participants with fluorodeoxyglucose (FDG)-avid disease

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Number · Percentage of participants
ORR by IRC Assessment Using Positron Emission Tomography-Computed Tomography (PET-CT)
Percentage of participantsZanubrutinib
ORR by IRC Assessment Using Positron Emission Tomography-Computed Tomography (PET-CT)69.5 (56.13 to 80.81)
SecondaryProgression-free Survival (PFS) by Investigator Assessment

PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using Lugano Classification

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Median · Months
Progression-free Survival (PFS) by Investigator Assessment
MonthsZanubrutinib
Progression-free Survival (PFS) by Investigator AssessmentNA (16.5 to NA)
SecondaryPFS Event-Free Rate by Investigator Assessment

PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for PFS at 24 months with 95% confidence intervals estimated using Greenwood's formula.

Time frame:
Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Reported as:
Number · Percentage of participants
PFS Event-Free Rate by Investigator Assessment
Percentage of participantsZanubrutinib
PFS Event-Free Rate by Investigator Assessment57.9 (44.83 to 68.86)
SecondaryPFS by IRC Assessment

PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by an IRC using Lugano Classification

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Median · Months
PFS by IRC Assessment
MonthsZanubrutinib
PFS by IRC AssessmentNA (27.6 to NA)
SecondaryPFS Event-Free Rate by IRC Assessment

PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for PFS at 24 months with 95% confidence intervals estimated using Greenwood's formula.

Time frame:
Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Reported as:
Number · Percentage of participants
PFS Event-Free Rate by IRC Assessment
Percentage of participantsZanubrutinib
PFS Event-Free Rate by IRC Assessment70.9 (57.20 to 80.95)
SecondaryOverall Survival (OS)

OS is defined as the time from first study drug administration to the date of death due to any cause

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsZanubrutinib
Overall Survival (OS)NA (NA to NA)
SecondaryOS Event-Free Rate

OS is defined as the time from first study drug administration to the date of death due to any cause. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for OS at 24 months with 95% confidence intervals estimated using Greenwood's formula.

Time frame:
Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Reported as:
Number · Percentage of participants
OS Event-Free Rate
Percentage of participantsZanubrutinib
OS Event-Free Rate85.9 (74.7 to 92.4)
SecondaryDuration of Response (DOR) by Investigator Assessment

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification.

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Median · Months
Duration of Response (DOR) by Investigator Assessment
MonthsZanubrutinib
Duration of Response (DOR) by Investigator AssessmentNA (22.1 to NA)
SecondaryDOR Event-Free Rate by Investigator Assessment

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 24 months with 95% confidence intervals estimated using Greenwood's formula.

Time frame:
Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Reported as:
Number · Percentage of participants
DOR Event-Free Rate by Investigator Assessment
Percentage of participantsZanubrutinib
DOR Event-Free Rate by Investigator Assessment60.8 (44.8 to 73.6)
SecondaryDOR by IRC Assessment

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using Lugano Classification.

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Median · Months
DOR by IRC Assessment
MonthsZanubrutinib
DOR by IRC AssessmentNA (25.0 to NA)
SecondaryDOR Event-Free Rate by IRC Assessment

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 24 months with 95% confidence intervals estimated using Greenwood's formula.

Time frame:
Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Reported as:
Number · Percentage of participants
DOR Event-Free Rate by IRC Assessment
Percentage of participantsZanubrutinib
DOR Event-Free Rate by IRC Assessment72.9 (54.4 to 84.9)
SecondaryTime to Treatment Failure (TTF)

TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason.

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Median · Months
Time to Treatment Failure (TTF)
MonthsZanubrutinib
Time to Treatment Failure (TTF)27.8 (14.7 to NA)
SecondaryTTF Event-Free Rate

TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for TTF at 24 months with 95% confidence intervals estimated using Greenwood's formula.

Time frame:
Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Reported as:
Number · Percentage of participants
TTF Event-Free Rate
Percentage of participantsZanubrutinib
TTF Event-Free Rate53.0 (40.4 to 64.2)
SecondaryTime to Next Line of Therapy

Time to next line of therapy is defined as the time from study treatment start to the start of the first subsequent therapy for MZL

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Median · Months
Time to Next Line of Therapy
MonthsZanubrutinib
Time to Next Line of TherapyNA (NA to NA)
SecondaryTime to Next Line of Therapy Event-Free Rate

Time to next line of therapy is defined as the time from study treatment start to the start of the first subsequent therapy for MZL. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for time to next line of therapy at 24 months with 95% confidence intervals estimated using Greenwood's formula.

Time frame:
Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Reported as:
Number · Percentage of participants
Time to Next Line of Therapy Event-Free Rate
Percentage of participantsZanubrutinib
Time to Next Line of Therapy Event-Free Rate74.5 (61.7 to 83.6)
SecondaryTime to Response (TTR) by Investigator Assessment

TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better) as assessed by the investigator using Lugano Classification

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Median · Months
Time to Response (TTR) by Investigator Assessment
MonthsZanubrutinib
Time to Response (TTR) by Investigator Assessment2.79 (1.7 to 16.6)
SecondaryTTR by IRC Assessment

TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better), as assessed by the IRC using Lugano Classification.

Time frame:
Up to approximately 3 years and 2.5 months
Reported as:
Median · Months
TTR by IRC Assessment
MonthsZanubrutinib
TTR by IRC Assessment2.79 (1.7 to 11.1)
SecondaryChange From Baseline in EuroQol 5-dimension 5-level (EQ-5D-5L) Visual Analogue Score (VAS)

Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' Positive change from baseline indicates improved health.

Time frame:
Baseline to Cycle 30 (28 days per cycle)
Reported as:
Mean · Score on a scale
Change From Baseline in EuroQol 5-dimension 5-level (EQ-5D-5L) Visual Analogue Score (VAS)
Score on a scaleZanubrutinib
Cycle 31.0 ± 18.18
Cycle 62.2 ± 15.78
Cycle 90.2 ± 16.28
Cycle 122.8 ± 16.15
Cycle 185.6 ± 17.68
Cycle 245.8 ± 15.24
Cycle 301.6 ± 18.15
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status

Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes global health status and quality of life questions related to their overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a positive score from baseline indicating improved health.

Time frame:
Baseline to Cycle 30 (28 days per cycle)
Reported as:
Mean · Score on a scale
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status
Score on a scaleZanubrutinib
Cycle 37.471 ± 19.5396
Cycle 67.823 ± 15.8121
Cycle 95.382 ± 20.0833
Cycle 127.143 ± 17.3216
Cycle 1810.677 ± 18.4811
Cycle 249.286 ± 19.2561
Cycle 306.250 ± 20.4910
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory tests, physical exams, and vital signs

Time frame:
From first dose to 30 days after last dose of study drug (Up to approximately 3 years and 2.5 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsZanubrutinib
At least one TEAE68
At least one SAE30
SecondaryArea Under the Curve From Time 0 to 6 Hours (AUC0-6)
Time frame:
Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
Reported as:
Mean · Hour*ng/mL
Area Under the Curve From Time 0 to 6 Hours (AUC0-6)
Hour*ng/mLZanubrutinib
Area Under the Curve From Time 0 to 6 Hours (AUC0-6)868.0 ± 304.3
SecondaryApparent Oral Clearance (CL/F) of Zanubrutinib
Time frame:
Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
Reported as:
Mean · Liters/hour
Apparent Oral Clearance (CL/F) of Zanubrutinib
Liters/hourZanubrutinib
Apparent Oral Clearance (CL/F) of Zanubrutinib215.3 ± 114.8
SecondaryMaximum Observed Concentration (Cmax)
Time frame:
Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
Reported as:
Mean · nanograms/milliliter
Maximum Observed Concentration (Cmax)
nanograms/milliliterZanubrutinib
Maximum Observed Concentration (Cmax)315.5 ± 120.2
SecondaryElimination Half Life (t1/2)
Time frame:
Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
Reported as:
Median · Hours
Elimination Half Life (t1/2)
HoursZanubrutinib
Elimination Half Life (t1/2)1.2 (0.8 to 2.7)

Adverse events

Collected over From first dose to 30 days after last dose of study drug (Up to approximately 3 years and 2.5 months). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib13/68 (19.1%)30/68 (44.1%)61/68 (89.7%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventZanubrutinib
COVID-19 pneumoniaInfections and infestations4/68
PyrexiaGeneral disorders3/68
PneumoniaInfections and infestations3/68
FallInjury, poisoning and procedural complications2/68
SyncopeNervous system disorders2/68
AnaemiaBlood and lymphatic system disorders1/68
PancytopeniaBlood and lymphatic system disorders1/68
Angina pectorisCardiac disorders1/68
Atrial fibrillationCardiac disorders1/68
Atrial flutterCardiac disorders1/68
Most frequent other events
Showing 10 of 46
Most frequent other events
EventZanubrutinib
ContusionInjury, poisoning and procedural complications16/68
DiarrhoeaGastrointestinal disorders15/68
ConstipationGastrointestinal disorders12/68
ArthralgiaMusculoskeletal and connective tissue disorders10/68
Upper respiratory tract infectionInfections and infestations9/68
Abdominal painGastrointestinal disorders8/68
PyrexiaGeneral disorders8/68
Back painMusculoskeletal and connective tissue disorders8/68
ThrombocytopeniaBlood and lymphatic system disorders7/68
NauseaGastrointestinal disorders7/68

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Zanubrutinib
Mean67.9 ± 11.41
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib
Female32
Male36
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zanubrutinib
Hispanic or Latino0
Not Hispanic or Latino58
Unknown or Not Reported10
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zanubrutinib
Asian13
White40
Multiple2
Other1
Unknown1
Not Reported11
08

Study locations

31 sites
  • Clinical Research Alliance, Inc
    Westbury, New York 11590, United States
  • The Charlotte Mecklenburg Hospital Authority
    Charlotte, North Carolina 28203, United States
  • Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • The Saint George Hospital Kogarah
    Kogarah, New South Wales 2217, Australia
  • Princess Alexandra Hospital
    Brisbane, Queensland 4102, Australia
  • Flinders Medical Centre
    Bedford PK, South Australia 5042, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Peninsula Private Hospital
    Frankston, Victoria 3199, Australia
  • Peking University Third Hospital
    Beijing, Beijing 100000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin 300020, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • University Hospital Vinohrady Hematology Department
    Prague, 10034, Czechia
  • Centre de Lutte Contre Le Cancer Institut Bergonie
    Bordeaux, 33076, France
  • Hopital de La Conception Aphm
    Marseille Cedex, 13005, France
  • Hopital Saint Louis
    Paris, 75010, France
  • Chu Hopital Lyon Sud
    PierreBenite, 69495, France
  • Policlinico Sorsola Malpighi, Aou Di Bologna
    Bologna, 40138, Italy
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • Universita Degli Studi Di Modena Azienda Ospedaliere Policlinco
    Modena, 41124, Italy
  • Azienda Ospedaliera S Maria Di Terni
    Terni, 05100, Italy
  • Ao Citta Della Salute E Della Scienza Di Torino Presidio O
    Torino, 10126, Italy
  • Severance Hospital Yonsei University Health System
    Seoul, Seoul Teugbyeolsi 03722, Korea, Republic of
  • Auckland City Hospital
    Auckland, 1023, New Zealand
  • North Shore Hospital
    Takapuna, 0622, New Zealand
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • The Christie Hospital
    Greater Manchester, M20 4BX, United Kingdom
  • University College Hospital
    London, NW1 2PG, United Kingdom
  • Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
09

References and documents

Publications

  • Stephen Opat, Robert Marcus, MA, FRCP, FRCPath, Craig A. Portell, MD, William Reed, MD, Chris Tankersley, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA. Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma. Blood. 2019; 134(1):5256. https://doi.org/10.1182/blood-2019-122629
  • Stephen Opat, et al. Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial. Presented at the 62nd American Society of Hematology (ASH) Annual Meeting, December 5-8, 2020. Abstract 339.
  • Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15. PubMed 34526366 ↗
  • Opat S, Tedeschi A, Hu B, et al: Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma. 2022 ASH Annual Meeting and Exposition. Abstract 234. Presented December 10, 2022.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in May 2022, 38 months.

Of 113 phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2018
First posted
Feb 19, 2019
StartActual
Feb 19, 2019
Primary completionActual
May 4, 2022
CompletionActual
May 4, 2022
Results first posted
Mar 3, 2022
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03846427
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Feb 19, 2019
Start date
Feb 19, 2019
Primary completion
May 4, 2022
Completion
May 4, 2022
Results posted
Mar 3, 2022
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion